Understanding epigenetics: The potential rationale for BET inhibition in management of CVD

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Prof. Jorge Plutzky explains BET inhibition as a novel therapeutic strategy for controlling pathologic cardiovascular responses.

Video navigation menu

Concept of coordinated programs in cardiometabolic states 00:23
Complex regulation through transcription factors 02:31
Another level of regulation through epigenetics 05:27
The role of BETs in transformation of cell states 09:09
Direct and indirect effects of BET inhibition on atherosclerosis 14:44

Educational information

This lecture was part of a CME accredited symposium: "LDL-c: Done Deal, Next Epigenetics?" during ESC 2018 in Munich, Germany.

Faculty

Jorge Plutzky, M.D. is Director, Preventive Cardiology at Brigham and Women’s Hospital (BWH), and is on the faculty of Harvard Medical School

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

View slides of prof. Plutzky

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.